Phase 2Completed
ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate
A Phase 2a, 4-Week, Double-Blind, Proof-of-Concept Efficacy and Safety Study of ACP-196 Versus Placebo in Subjects With Active Rheumatoid Arthritis on Background Methotrexate
- Sponsor
- Acerta Pharma BV (Industry)
- Enrolment
- 31 enrolled
- Conditions
- Rheumatoid Arthritis
- Interventions
- acalabrutinib; Placebo
- Ages
- adults, older adults
- Registry
- NCT02387762
Full record on ClinicalTrials.gov
From the registry
This study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of ACP-196 in subjects with Rheumatoid Arthritis on background Methotrexate.
Primary outcomes
- Disease Activity Score 28-CRP (DAS28-CRP) at Week 4
History
Last registry update
Results first posted
Study completion
Primary completion
Started
Registered